Nutcracker Therapeutics, Inc.
5858 Horton Street, Suite 540
Emeryville
CA
94608
United States
Tel: 13104805538
Website: https://www.nutcrackerx.com/
17 articles about Nutcracker Therapeutics, Inc.
-
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
4/11/2024
Nutcracker Therapeutics, Inc recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, NTX-470; and the other highlighting data on the immunomodulatory cytokine, LIGHT.
-
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024
3/12/2024
Nutcracker Therapeutics, Inc. today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
-
Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
1/8/2024
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer.
-
Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting
11/7/2023
Nutcracker Therapeutics, Inc. today presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250.
-
Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023
10/24/2023
Nutcracker Therapeutics, Inc. today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4.
-
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors
5/9/2023
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, announced the appointment of Cynthia Collins to the company’s board of directors.
-
Nutcracker Therapeutics Presenting on Nutshell™ mRNA Delivery Technology at the 2023 Oligonucleotide and Peptide Therapeutics Conference
5/2/2023
Nutcracker Therapeutics, Inc. will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA.
-
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting
4/19/2023
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
-
Nutcracker Therapeutics Appoints Industry Veteran Angela Peters as Chief Human Resources Officer
3/7/2023
Nutcracker Therapeutics, Inc. today announced the appointment of Angela Peters as the company’s first Chief Human Resources Officer (CHRO).
-
Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors
2/6/2023
Nutcracker Therapeutics, Inc. today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors.
-
Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022
11/11/2022
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.
-
Nutcracker Therapeutics to Present Data for Lead Candidate at 2022 SITC Annual Meeting
10/13/2022
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
-
Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer
9/12/2022
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer.
-
Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline
6/22/2022
Nutcracker Therapeutics reveals oncology-focused pipeline programs, with lead candidate in IND-enabling studies.
-
Money on the Move: March 9-15
3/16/2022
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates. -
Two oncology-focused biotechnology firms generated a total of $247 million in additional funding to support their respective research and development efforts for cancer treatment.